tiprankstipranks
Kromek Group PLC (GB:KMK)
LSE:KMK

Kromek Group plc (KMK) AI Stock Analysis

28 Followers

Top Page

GB:KMK

Kromek Group plc

(LSE:KMK)

Select Model
Select Model
Select Model
Outperform 73 (OpenAI - 5.2)
Rating:73Outperform
Price Target:
11.00 p
▲(29.41% Upside)
Action:ReiteratedDate:01/14/26
The score is driven primarily by improved financial performance (strong revenue growth, expanding margins, and low leverage), tempered by mixed free cash flow trends. Technicals are supportive due to a strong uptrend and positive MACD, but overbought RSI/Stoch readings add pullback risk. Valuation is moderate on a 20.508 P/E with no dividend yield.
Positive Factors
Strong Revenue Growth
Sustained, large top-line expansion indicates strengthening product-market fit and growing traction across its target end markets. Over a 2-6 month horizon this underpins recurring program wins, improves bargaining power with OEMs and supports reinvestment into R&D and scale-up of production.
Negative Factors
Negative Free Cash Flow Growth
Negative FCF growth despite operating cash covering net income suggests working capital, capex or timing effects that can constrain internally funded expansion. Over months this may require external financing for larger program fulfilment or slow down planned investment into product scaling.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Revenue Growth
Sustained, large top-line expansion indicates strengthening product-market fit and growing traction across its target end markets. Over a 2-6 month horizon this underpins recurring program wins, improves bargaining power with OEMs and supports reinvestment into R&D and scale-up of production.
Read all positive factors

Kromek Group plc (KMK) vs. iShares MSCI United Kingdom ETF (EWC)

Kromek Group plc Business Overview & Revenue Model

Company Description
Kromek Group plc (KMK) is a UK-based technology company that specializes in advanced radiation detection solutions. The company operates primarily in the sectors of security, medical imaging, and nuclear instrumentation. Kromek's core products inc...
How the Company Makes Money
Kromek makes money by selling radiation detection and imaging products and, where applicable, associated services into government, defense/security, nuclear, and medical markets. Its revenue model is primarily product-led and typically includes: (...

Kromek Group plc Financial Statement Overview

Summary
Strong income statement recovery (65.83% revenue growth, 80.85% gross margin, positive 14.16% net margin) and a solid balance sheet (low 0.08 debt-to-equity, 79.22% equity ratio). Cash flow is the main offset, with negative free cash flow growth despite good cash conversion (operating cash flow to net income of 1.72).
Income Statement
85
Very Positive
Balance Sheet
78
Positive
Cash Flow
70
Positive
BreakdownTTMApr 2024Apr 2023Apr 2022Apr 2021Apr 2020
Income Statement
Total Revenue37.84M26.51M19.40M17.31M12.05M10.35M
Gross Profit28.58M21.43M10.71M6.04M3.07M2.65M
EBITDA14.16M6.16M2.93M-1.25M-1.23M-1.74M
Net Income12.50M3.75M-3.29M-6.10M-4.92M-5.35M
Balance Sheet
Total Assets65.75M65.87M70.19M63.88M67.42M70.16M
Cash, Cash Equivalents and Short-Term Investments1.25M1.70M466.00K1.10M5.08M15.60M
Total Debt7.81M4.05M12.29M13.38M11.00M12.86M
Total Liabilities8.87M13.69M20.84M22.35M19.99M20.10M
Stockholders Equity56.88M52.18M49.35M41.52M47.44M50.05M
Cash Flow
Free Cash Flow17.12M15.71M-7.84M-5.78M-10.29M-7.69M
Operating Cash Flow17.46M15.90M-2.80M-504.00K-3.84M-1.62M
Investing Cash Flow-4.80M-4.55M-5.00M-5.27M-6.45M-6.07M
Financing Cash Flow-10.54M-9.19M7.18M1.99M-1.23M14.13M

Kromek Group plc Technical Analysis

Technical Analysis Sentiment
Positive
Last Price8.50
Price Trends
50DMA
10.79
Negative
100DMA
9.55
Positive
200DMA
7.69
Positive
Market Momentum
MACD
-0.31
Negative
RSI
45.49
Neutral
STOCH
64.25
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:KMK, the sentiment is Positive. The current price of 8.5 is below the 20-day moving average (MA) of 10.03, below the 50-day MA of 10.79, and above the 200-day MA of 7.69, indicating a neutral trend. The MACD of -0.31 indicates Negative momentum. The RSI at 45.49 is Neutral, neither overbought nor oversold. The STOCH value of 64.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:KMK.

Kromek Group plc Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
77
Outperform
£534.43M10.738.34%2.09%0.49%61.73%
73
Outperform
£65.18M3.5722.93%36.61%
69
Neutral
£283.07M31.2212.26%1.89%5.46%-26.44%
67
Neutral
£208.56M25.563.10%2.19%10.66%21.19%
61
Neutral
$37.18B12.37-10.20%1.83%8.50%-7.62%
54
Neutral
£213.67M-4.02-31.21%-16.33%-448.12%
39
Underperform
£27.57M-21.06-12.60%-14.81%-1362.50%
* Technology Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
GB:KMK
Kromek Group plc
9.95
5.10
105.15%
GB:GHH
Gooch & Housego
762.00
399.39
110.14%
GB:JDG
Judges Scientific
4,250.00
-2,253.76
-34.65%
GB:TTG
TT Electronics
120.00
42.00
53.85%
GB:WPHO
Windar Photonics
28.50
-13.00
-31.33%
GB:DSCV
discoverIE Group plc
556.00
79.10
16.59%

Kromek Group plc Corporate Events

Other
Kromek Chairman Increases Stake with Fresh Share Purchase
Positive
Mar 9, 2026
Kromek Group plc reported that its non-executive chairman, Rakesh Sharma, has increased his personal stake in the company by purchasing 102,669 ordinary shares at 9.74p each. Following this transaction, Sharma now holds 1,310,208 shares, represent...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Kromek Swings to Profit on Siemens-Backed Imaging Surge and Strong CBRN Demand
Positive
Jan 20, 2026
Kromek Group reported a sharp turnaround in performance for the six months to 31 October 2025, with revenue surging to £15.0m from £3.7m a year earlier and a move from a pre-tax loss of £5.7m to a £3.1m profit, driven by strong...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jan 14, 2026